Complete Response • 25%

Partial Response • 25%

Stable Disease • 25%

Progressive Disease • 25%

Positive results • 25%

Negative results • 25%

Mixed results • 25%

No results announced • 25%

Successful • 33%

Partially Successful • 33%

Unsuccessful • 33%

Completed with positive results • 25%

Completed with negative results • 25%

Not completed • 25%

Unknown/Other • 25%

Significant Improvement • 33%

No Change • 33%

Significant Adverse Effects • 34%

Clinical hold • 25%

No action • 25%

Request for additional data • 25%

Other • 25%

Successful with significant efficacy • 25%

Successful with moderate efficacy • 25%

Unsuccessful due to adverse effects • 25%

Unsuccessful due to lack of efficacy • 25%

Positive efficacy and safety results • 25%

Positive efficacy, but safety concerns • 25%

Negative efficacy, but good safety • 25%

Negative efficacy and safety concerns • 25%

Yes • 50%

No • 50%

Positive outcome with significant efficacy • 25%

Mixed outcome with limited efficacy • 25%

Negative outcome with no efficacy • 25%

Trial terminated early due to safety concerns • 25%

Positive results • 25%

Negative results • 25%

Inconclusive results • 25%

Trial extended • 25%

Meets primary endpoint • 25%

Fails primary endpoint • 25%

Mixed results • 25%

Trial not completed by end of 2025 • 25%